The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice

Genes and Development

Volumn 20, Issue 12, 2006, Pages 1569-1574

  Chen, Mei Ling ^a   Xu, Pei Zhang ^a   Peng, Xiao Ding ^a   Chen, William S ^a   Guzman, Grace ^a   Yang, Ximing ^b   Di Cristofano, Antonio ^c   Pandolfi, Pier Paolo ^d   Hay, Nissim ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer therapy; Endometrium carcinoma; Intestinal polyps; PIN; Thyroid and adrenal tumors

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADRENAL MEDULLA TUMOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CARCINOMA; ENZYME DEFICIENCY; FEMALE; HAPLOTYPE; INTESTINE POLYP; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; THYROID TUMOR;

ADRENAL GLAND NEOPLASMS; ANIMALS; ENDOMETRIAL NEOPLASMS; FEMALE; HETEROZYGOTE; INTESTINAL POLYPS; MALE; MICE; NEOPLASMS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PSEUDOLYMPHOMA; PTEN PHOSPHOHYDROLASE; THYROID NEOPLASMS;

EID: 33745172528     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1395006     Document Type: Article

References (17)

1. Brazil, D.P. and Hemmings, B.A. 2001. Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem. Sci. 26: 657-664.
2. Cantley, L.C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657.
3. Chen, W.S., Xu, P.Z., Gottlob, K., Chen, M.L., Sokol, K., Shiyanova, T., Roninson, I., Weng, W., Suzuki, R., Tobe, K., et al. 2001. Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes & Dev. 15: 2203-2208.
4. Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G., and Sawyers, C.L. 2004. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10: 33-39.
5. DeFeo-Jones, D., Barnett, S.F., Fu, S., Hancock, P.J., Haskell, K.M., Leander, K.R., McAvoy, E., Robinson, R.G., Duggan, M.E., Lindsley, C.W., et al. 2005. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 4: 271-279.
6. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., and Pandolfi, P.P. 1998. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19: 348-355.
7. Ellenson, L.H. and Wu, T.C. 2004. Focus on endometrial and cervical cancer. Cancer Cell 5: 533-538.
8. Hay, N. 2005. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
9. Kandel, E.S. and Hay, N. 1999. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp. Cell Res. 253: 210-229.
10. Lindsley, C.W., Zhao, Z., Leister, W.H., Robinson, R.G., Barnett, S.F., Defeo-Jones, D., Jones, R.E., Hartman, G.D., Huff, J.R., Huber, H.E., et al. 2005. Allosteric Akt (PKB) inhibitors: Discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15: 761-764.
11. Park, J.H., Walls, J.E., Galvez, J.J., Kim, M., Abate-Shen, C., Shen, M.M., and Cardiff, R.D. 2002. Prostatic intraepithelial neoplasia in genetically engineered mice. Am. J. Pathol. 161: 727-735.
12. Peng, X.D., Xu, P.Z., Chen, M.L., Hahn-Windgassen, A., Skeen, J., Jacobs, J., Sundararajan, D., Chen, W.S., Crawford, S.E., Coleman, K.G., et al. 2003. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes & Dev. 17: 1352-1365.
13. Podsypanina, K., Ellenson, L.H., Nemes, A., Gu, J., Tamura, M., Yamada, K.M., Cordon-Cardo, C., Catoretti, G., Fisher, P.E., and Parsons, R. 1999. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. 96: 1563-1568.
14. Sansal, I. and Sellers, W.R. 2004. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22: 2954-2963.
15. Shappell, S.B., Thomas, G.V., Roberts, R.L., Herbert, R., Ittmann, M.M., Rubin, M.A., Humphrey, P.A., Sundberg, J.P., Rozengurt, N., Barrios, R., et al. 2004. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 64: 2270-2305.
16. Suzuki, A., de la Pompa, J.L., Stambolic, V., Elia, A.J., Sasaki, T., del Barco Barrantes, I., Ho, A., Wakeham, A., Itie, A., Khoo, W., et al. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8: 1169-1178.
17. Wymann, M.P. and Marone, R. 2005. Phosphoinositide 3-kinase in disease: Timing, location, and scaffolding. Curr. Opin. Cell Biol. 17: 141-149.